Patents by Inventor Hans Jasper GENEE

Hans Jasper GENEE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11851461
    Abstract: The invention provides a genetically modified bacterial cell capable of improved iron-sulfur cluster delivery, characterized by a modified gene encoding a mutant Iron Sulfur Cluster Regulator (IscR) as well as one or more transgenes encoding polypeptides that enhance the biosynthesis of either biotin, lipoic acid or thiamine. The invention provides a method for producing either biotin, lipoic acid or thiamine using the genetically modified bacterium of the invention; as well as for the use of the genetically modified bacterial cell for either biotin, lipoic acid or thiamine production.
    Type: Grant
    Filed: July 12, 2018
    Date of Patent: December 26, 2023
    Assignee: BIOSYNTIA APS
    Inventors: Hans Jasper Genee, Anne Pihl Bali, Nils Myling-Petersen
  • Publication number: 20230192778
    Abstract: The invention provides a genetically modified bacterial cell capable of improved iron-sulfur cluster delivery, characterized by a modified gene encoding a mutant Iron Sulfur Cluster Regulator (IscR) as well as one or more transgenes encoding polypeptides that enhance the biosynthesis of either biotin, lipoic acid or thiamine. The invention provides a method for producing either biotin, lipoic acid or thiamine using the genetically modified bacterium of the invention; as well as for the use of the genetically modified bacterial cell for either biotin, lipoic acid or thiamine production.
    Type: Application
    Filed: July 12, 2018
    Publication date: June 22, 2023
    Applicant: BIOSYNTIA APS
    Inventors: Hans Jasper GENEE, Anne Pihl BALI, Nils MYLING-PETERSEN
  • Publication number: 20220127311
    Abstract: The invention relates to a genetically modified prokaryotic cell capable of improved iron-sulfur cluster delivery, characterized by a modified gene encoding a mutant Iron Sulfur Cluster Regulator (IscR) and one or more transgenes or upregulated endogenous genes encoding iron-sulfur (Fe—S) cluster polypeptides or proteins that catalyze complex radical-mediated molecular rearrangements, electron transfer, radical or non-redox reactions, sulfur donation or perform regulatory functions. The prokaryotic cells are characterized by enhanced activity of these iron-sulfur (Fe—S) cluster polypeptides, enhancing their respective functional capacity, and facilitating enhanced yields of compounds in free and protein-bound forms, including heme, hemoproteins, tetrapyrroles, B vitamins, amino acids, ?-aminolevulinic acid, biofuels, isoprenoids, pyrroloquinoline quinone, ammonia, indigo, or their precursors, whose biosynthesis depends on their activity.
    Type: Application
    Filed: January 15, 2020
    Publication date: April 28, 2022
    Applicant: BIOSYNTIA APS
    Inventors: Hans Jasper GENEE, Carlos G. ACEVE-DO-ROCHA, Anne Pihl BALI, Lasse Holm LAURIDSEN, Luisa GRONENBERG, Nils MYLING-PETERSEN
  • Publication number: 20200332303
    Abstract: The present invention relates to a regulatable gene expression construct comprising a nucleic acid molecule comprising two or more regulation sequences encoding respective RNA molecules comprising a riboswitch responsive to an effector compound, said riboswitch being operably linked to a respective coding region which encodes a respective modulator compound for modulating the action of a respective growth regulator compound and each said riboswitch in each regulation sequence being selected be responsive to the same effector compound to trigger expression of its respective modulator compound. The invention also relates to a method of using the regulatable gene expression construct for selecting from a metagenomic library a primary modulator compound which effects a chemical transformation of a substrate into said effector compound or transports said effector compound into a micro-organism comprising the regulatable gene expression construct.
    Type: Application
    Filed: May 12, 2020
    Publication date: October 22, 2020
    Applicant: BIOSYNTIA APS
    Inventors: Hans Jasper GENEE, Morten SOMMER
  • Patent number: 10696992
    Abstract: The invention provides a genetically modified bacterium for production of thiamine; where the bacterium is characterized by a transgene encoding a thiamine monophosphate phosphatase (TMP phosphatase having EC 3.1.3.-) as well as transgenes encoding polypeptides that catalyze steps in the thiamine pathway. The genetically modified bacterium is characterized by enhanced synthesis and release of thiamine into the extracellular environment. The invention further provides a method for producing thiamine using the genetically modified bacterium of the invention; as well as the use of the genetically modified bacterium for extracellular thiamine production.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: June 30, 2020
    Assignee: BIOSYNTHIA APS
    Inventors: Luisa Gronenberg, Bo Salomonsen, Matteo Ferla, Hans Jasper Genee
  • Publication number: 20190382815
    Abstract: The invention provides a genetically modified bacterium for production of thiamine; where the bacterium is characterized by a transgene encoding a thiamine monophosphate phosphatase (TMP phosphatase having EC 3.1.3.-) as well as transgenes encoding polypeptides that catalyze steps in the thiamine pathway. The genetically modified bacterium is characterized by enhanced synthesis and release of thiamine into the extracellular environment. The invention further provides a method for producing thiamine using the genetically modified bacterium of the invention; as well as the use of the genetically modified bacterium for extracellular thiamine production.
    Type: Application
    Filed: December 16, 2016
    Publication date: December 19, 2019
    Applicant: BIOSYNTIA APS
    Inventors: Luisa GRONENBERG, Bo SALOMONSEN, Matteo FERLA, Hans Jasper GENEE
  • Publication number: 20160186187
    Abstract: The present invention relates to a regulatable gene expression construct comprising a nucleic acid molecule comprising two or more regulation sequences encoding respective RNA molecules comprising a riboswitch responsive to an effector compound, said riboswitch being operably linked to a respective coding region which encodes a respective modulator compound for modulating the action of a respective growth regulator compound and each said riboswitch in each regulation sequence being selected be responsive to the same effector compound to trigger expression of its respective modulator compound. The invention also relates to a method of using the regulatable gene expression construct for selecting from a metagenomic library a primary modulator compound which effects a chemical transformation of a substrate into said effector compound or transports said effector compound into a micro-organism comprising the regulatable gene expression construct.
    Type: Application
    Filed: May 20, 2014
    Publication date: June 30, 2016
    Inventors: Hans Jasper GENEE, Morten SOMMER